Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 12/20 | 0.38 |
| ▸ | DRD2 | P14416 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL216099 | 0.94 | MAPT (0.39) | DRD3DRD2MAPTKMT2AKDM4E | |
| SCHEMBL213711 | 0.92 | ALDH1A1 (0.38) | DRD3DRD2MAPTKMT2AKDM4E | |
| SCHEMBL214594 | 0.91 | ATM (0.41) | MAPTKMT2APDE3BPDE3AMEN1 | |
| Hydrochloric Acid SCHEMBL213385 | 0.91 | MAPT (0.38) | DRD3DRD2MAPTKMT2AKDM4E | |
| SCHEMBL213821 | 0.90 | HRH4 (0.42) | DRD3DRD2MAPTKMT2AKDM4E | |
| SCHEMBL213244 | 0.90 | ALDH1A1 (0.38) | DRD2MAPTKMT2AKDM4EALDH1A1 | |
| SCHEMBL213924 | 0.90 | ALDH1A1 (0.40) | MAPTKMT2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL213685 | 0.88 | ALDH1A1 (0.38) | MAPTKMT2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL216125 | 0.88 | ATM (0.41) | MAPTKMT2APDE3BPDE3AMEN1 | |
| SCHEMBL215366 | 0.88 | LMNA (0.43) | MAPTKMT2AKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | DRD3 4551/4885DRD2 3081/4885MAPT 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.